EUVIMEDEUVIMED entdecken
Open Access

Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data

Ioannis Tomazos, Anthony J Hatswell, Spero Cataland, Peter Chen, Nick Freemantle, Åsa Lommele, Kevin Deighton, Emma Knowles, Neil S Sheerin, Eric Rondeau

Clinical Nephrology · 01.05.2022 · 97 (5) · 261-272

DOI: 10.5414/cn110516 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Nephrology, erschienen am 01.05.2022. Verfasst von Ioannis Tomazos und 9 weiteren Autor:innen. Hauptthemen laut MEDLINE: Atypical Hemolytic Uremic Syndrome. Die Arbeit wurde bisher 34-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atypical Hemolytic Uremic SyndromeAdultAntibodies, Monoclonal, HumanizedFemaleHumansMaleQuality of Life

Substanzen

Antibodies, Monoclonal, Humanizedeculizumabravulizumab

Zitieren

APA

Tomazos, I., Hatswell, A. J., Cataland, S., Chen, P., Freemantle, N., Lommele, Å., Deighton, K., Knowles, E., Sheerin, N. S., & Rondeau, E. (2022). Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data. Clinical Nephrology, 97(5), 261-272. https://doi.org/10.5414/cn110516

Vancouver

Tomazos I, Hatswell AJ, Cataland S, Chen P, Freemantle N, Lommele Å, et al. Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data. Clinical Nephrology. 2022;97(5):261-272. doi:10.5414/cn110516

BibTeX
@article{Tomazos2022,
  author = {Tomazos, Ioannis and Hatswell, Anthony J and Cataland, Spero and Chen, Peter and Freemantle, Nick and Lommele, Åsa and Deighton, Kevin and Knowles, Emma and Sheerin, Neil S and Rondeau, Eric},
  title = {Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data},
  journal = {Clinical Nephrology},
  year = {2022},
  volume = {97},
  number = {5},
  pages = {261--272},
  doi = {10.5414/cn110516}
}
Kostenlos starten →